First Time Loading...

Taro Pharmaceutical Industries Ltd
NYSE:TARO

Watchlist Manager
Taro Pharmaceutical Industries Ltd Logo
Taro Pharmaceutical Industries Ltd
NYSE:TARO
Watchlist
Price: 42.4 USD -0.19% Market Closed
Updated: Apr 28, 2024
Section:
 

Relative Value

The Relative Value of one TARO stock under the Base Case scenario is 20.23 USD. Compared to the current market price of 42.4 USD, Taro Pharmaceutical Industries Ltd is Overvalued by 52%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TARO Relative Value
Base Case
20.23 USD
Overvaluation 52%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.6
P/S
P/S
Price to Sales
2.6
vs History
63
vs Industry
43
Median 3Y
2.6
Median 5Y
3.7
Industry
2.4
Forward
2.5
More Details
34.9
P/E
P/E
Price to Earnings
34.9
vs History
30
vs Industry
13
Median 3Y
35
Median 5Y
17.2
Industry
22.9
Forward
37.8
More Details
11.2
P/OCF
P/OCF
Price to OCF
11.2
vs History
49
vs Industry
33
Median 3Y
11.4
Median 5Y
11.2
Industry
17.1
More Details
18.5
P/FCFE
P/FCFE
Price to FCFE
18.5
vs History
34
vs Industry
23
Median 3Y
18.4
Median 5Y
14
Industry
23.2
More Details
0.9
P/B
P/B
Price to Book Value
0.9
vs History
61
vs Industry
65
Median 3Y
0.9
Median 5Y
1.2
Industry
2.1
More Details
1.1
EV/S
EV/S
Enterprise Value to Sales
1.1
vs History
65
vs Industry
69
Median 3Y
1.1
Median 5Y
2
Industry
2.6
Forward
1.1
More Details
2.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.4
vs History
65
vs Industry
69
Median 3Y
2.3
Median 5Y
3.6
Industry
5.1
More Details
12.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.4
vs History
6
vs Industry
29
Median 3Y
8.8
Median 5Y
6.8
Industry
13.6
More Details
31.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
31.4
vs History
7
vs Industry
13
Median 3Y
8.1
Median 5Y
7.7
Industry
17
Forward
-546.3
More Details
4.8
EV/OCF
EV/OCF
Enterprise Value to OCF
4.8
vs History
63
vs Industry
46
Median 3Y
4.8
Median 5Y
6.1
Industry
15.8
More Details
8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
8
vs History
44
vs Industry
31
Median 3Y
7.8
Median 5Y
7.9
Industry
17.6
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
61
vs Industry
73
Median 3Y
0.6
Median 5Y
0.9
Industry
1.9
More Details

Multiples Across Competitors

TARO Competitors Multiples
Taro Pharmaceutical Industries Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
Taro Pharmaceutical Industries Ltd
NYSE:TARO
1.6B USD 2.6 34.9 12.4 31.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
696.4B USD 20.4 132.9 60.1 68.9
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 17 47.2 34.6 37.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY 255.8 9 733.7 1 771.8 4 320.3
US
Johnson & Johnson
NYSE:JNJ
351.8B USD 4.3 8.7 11.6 15.3
US
Merck & Co Inc
NYSE:MRK
332.2B USD 5.5 910 45.2 88.2
UK
AstraZeneca PLC
LSE:AZN
185.8B GBP 5.1 39 140.5 225.4
CH
Novartis AG
SIX:NOVN
182.9B CHF 4.3 13.5 9.9 16.3
CH
Roche Holding AG
SIX:ROG
176.2B CHF 3 15.3 8.5 10

See Also

Summary
TARO intrinsic value, competitors valuation, and company profile.
DCF Valuation
TARO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TARO stock valuation using valuation multiples.
Wall Street Estimates
TARO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TARO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.